|
| |
|
|
| |
As pharmaceutical companies struggle to improve their R&D productivity and smaller biotech companies try to access additional capacities and expertise with their limited budget, outsourcing is increasingly emerging as a major opportunity. China, with its large pool of qualified life science professionals and deep brain reserve overseas, has emerged as an attractive partner for cost-effective drug development. Companies can gain significant benefit in terms of a competitive edge through 30 to 40% cost savings, reduction in time-to-data, and rapid capacity expansion, while freeing their in-house resources for high value adding core activities. In many cases, service providers can conduct research with higher expertise and shorter turn-around time than can their customers. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
